{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidytjpbqhxpwnhhukqktbcuc23p6mfzu56zewneughslqhb73naoi",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mg3sfd5yimo2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/03/02/trump-europe-pharma-prices-340b-pharmacies-merck-glp1/?utm_campaign=rss",
  "publishedAt": "2026-03-02T13:52:56.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings",
  "title": "STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more",
  "updatedAt": "2026-03-02T13:53:00.000Z"
}